Table 6.

Randomized trials of cranial radiation therapy plus radiosensitizer in patients with brain metastases

StudyYearNo. patientsREGy/no. fractionsMedian survival time (mo), WBRT + RE vs WBRT
DeAngelis et al. (19)198958Lonidamine30/103.9 vs 5.4
Eyre et al. (61)1984111Metronidazole30/103.0 vs 3.5
Komarnicky et al. (62)1991779Misonidazole30/6-103.9
Phillips et al. (63)199572BrdUrd37.5/154.3 vs 6.1
Mehta et al. (39)2003401MGd30/205.2 vs 4.9
251 NSCLCNot reached vs 7.4*
Suh (64)20045-38Efaproxiral30/105.4 vs 4.4
Stea et al. (65)2004107 BCA4.5 vs 8.6*
Shaw et al. (66)200357Efaproxiral30/106.4 vs 4.1*
  • Abbreviations: RE, radioenhancer; BrdUrd, bromodeoxyuridine; MGd, motexafin gadolinium; NSCLC, non–small cell lung cancer; BCA, breast cancer.

  • * P < 0.05.